دورية أكاديمية

Biodegradable Intrascleral Implant of Triamcinolone Acetonide in Experimental Uveitis.

التفاصيل البيبلوغرافية
العنوان: Biodegradable Intrascleral Implant of Triamcinolone Acetonide in Experimental Uveitis.
المؤلفون: Jae Pil Shin, Yong Chul Park, Ji Hae Oh, Ji Woong Lee, Yu Mi Kim, Jeong Ok Lim, Si Yeol Kim
المصدر: Journal of Ocular Pharmacology & Therapeutics; Jun2009, Vol. 25 Issue 3, p201-208, 8p, 1 Color Photograph, 3 Graphs
مصطلحات موضوعية: TRIAMCINOLONE, TRIAMCINOLONE acetonide, ANTI-inflammatory agents, GLUCOCORTICOIDS, MYCOBACTERIUM tuberculosis, BRONCHODILATOR agents
مستخلص: Purpose: To evaluate the efficacy of a biodegradable intrascleral implant of triamcinolone acetonide (TA) in a rabbit model of experimental uveitis. Methods: A disc-shaped TA implant (1 × 3 mm, containing 6.4 mg of TA), which is made by poly(,-lactide) (PLA) and TA, was intrasclerally implanted into eight albino rabbits after a subcutaneous injection of tuberculin antigen. Control animals ( n = 8) received sham devices. Uveitis was induced with an intravitreal injection of tuberculin antigen. To induce chronic inflammation, all eyes were reinjected with intravitreal antigen on day 14 and were observed for 1 month. Aqueous protein concentrations and cell counts were determined on days 7, 14, and 28. Inflammation of the anterior chamber (AC) and vitreous opacity were graded clinically and retinal functions were evaluated electroretinographically and histologically. Results: Anterior chamber cells, flare, and vitreous opacity scores showed significantly less inflammation in treated eyes than in untreated eyes ( P < 0.05). Quantitative analyses of aqueous cell counts and protein concentrations showed significant decreases in treated eyes ( P < 0.05). Histopathologic examinations showed less severe inflammation and tissue disorganization in treated eyes. Conclusions: The biodegradable intrascleral TA implant was found to be effective at suppressing the inflammation induced by experimental uveitis in rabbits for at least 4 weeks. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Ocular Pharmacology & Therapeutics is the property of Mary Ann Liebert, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10807683
DOI:10.1089/jop.2008.0086